Data from this randomised, double-blind, placebo-controlled phase 3
study oral BG-12 in relapsing remitting MS (RRMS) shows a reduction in
annualised relapse rate of approximately 50% compared to placebo.
there was also a relative risk reduction for disability progression in
treated patients of approximately a third. Using a three-times-a-day
dosing regime was no superior to the twice-a-day dosing regimen.
Authors: Gold R, Kappos L, Arnold DL, Bar-Or A,
Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI,
Dawson KT; DEFINE Study Investigators.
Source: N Engl J Med. 2012 Sep 20;367(12):1098-107.
Read the abstract